• H. Lundbeck A/S, of Copenhagen, Denmark, and Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, reported data showing significant improvements in overall symptoms of depression in elderly patients taking Lu AA21004, with patients taking 5 mg of the multimodal depression drug showing a significantly greater (p = 0.0011) improvement on the primary efficacy endpoint of HAM-D24 total score vs. placebo at week eight.